Sir Harpal Kumar
Sir Harpal Kumar
Harpal gained a Masters in Chemical Engineering from the University of Cambridge and an MBA as a Baker Scholar from Harvard Business School. He has been awarded Honorary Doctorates from the University of Manchester and the University of Newcastle. He was knighted in the 2016 New Year's Honours list for services to cancer research.
After a brief period working as a research scientist with the UK Atomic Energy Authority, Harpal worked for four years in the London office of McKinsey and Co, specialising in healthcare. He then became CEO of The Papworth Trust, which focuses on pioneering rehabilitation services for people with acquired and congenital disabilities.
Harpal left Papworth in 1997 to become founding CEO of Nexan Group, a venture capital-backed medical device company, creating and marketing novel cardio-respiratory monitoring technologies to reduce premature mortality in patients with congestive heart failure.
Harpal joined Cancer Research Technology (CRT, a wholly-owned subsidiary of Cancer Research UK) as Chief Executive in October 2002. In addition to his role with CRT, he became Chief Operating Officer of Cancer Research UK in July 2004, before becoming Chief Executive in April 2007.
Harpal was Chair of the Taskforce and author of Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020, published in summer 2015. He is a Trustee of The Francis Crick Institute in London. He is a member of the National Cancer Transformation Board and chairs the National Cancer Advisory Group.
Harpal is also Innovation Champion for UK Research and Innovation and a member of the Innovate UK council.